Survivorship care in Canadian genitourinary oncology: Toward a multidisciplinary perspective.
Sue Richter(Princess Margaret Cancer Centre), Michael A.S. Jewett(Princess Margaret Cancer Centre), Nafisha Lalani(University of Toronto), David Wiljer(Oslo University Hospital), Srikala S. Sridhar(Princess Margaret Cancer Centre), Jacqueline L. Bender(University of Toronto), Pamela Catton(University Health Network), Nour Alkazaz(Princess Margaret Cancer Centre), M. Maganti(University of Toronto), Ashraf Almatar(Princess Margaret Cancer Centre), Christine Massey(University of Vermont), Laura Legere(Princess Margaret Cancer Centre)
Cited by 2
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841